Oculeve, Inc.
7
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
Role: lead
Tear Production by Nasal Neurostimulation Compared to Active Control
Role: lead
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
Role: lead
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Role: lead
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
Role: lead
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
Role: lead
The Effect of Electrical Stimulation on Tear Production
Role: lead
All 7 trials loaded